Flaxseed as well as its oil component possess antitumor activities against different types of cancer and have been used by some patients as complementary and/or alternative medicine. Linoorbitides (LOBs) are one family of flaxseed compounds that has implications for anticancer and antioxidant activity. The
Introduction
The nutraceutical effects of flaxseed have attracted significant research attention in recent years, leading to the identification and isolation of various families of bioactive compounds [1] [2] [3] [4] . Linoorbitides (LOBs) are a group of thermostable hydrophobic cyclopeptide compounds present in flaxseed oil. It has been noticed that cyclic peptides occur widely in both plants and animals and they can be broadly classified into two groups, cyclopeptides and cyclotides [5] . Various types of cyclopeptide have been isolated from plants and showed important biological functions such as anticancer, antidiabetic, cardio-protective and immunosuppressive properties, making them an abundant resource for future development of therapeutic agents [6, 7, [8] [9] [10] [11] [12] [13] . For example, sunflower trypsin inhibitor 1 (SFTI-1), a cyclopeptide containing 14-amino acids, has been used as the template to develop potent inhibitors of matriptase, which is present on the surface of certain types of cancer cells [14, 15] .
Many cancer patients seek treatments with complementary and/or alternative medicine (CAM), especially when they have developed drug resistance towards chemotherapies. According to the 2007 Statistics on CAM Use in the United States, 23% of American cancer patients use CAM [16] . The actual number is likely to be higher as many cancer patients do not tell their physicians or oncologists about CAM usage. Flaxseed as well as its oil component have been observed to exhibit antitumor activities towards different types of cancer [12, [17] [18] [19] , making flaxseed a CAM candidate for human cancer treatment. Flaxseed oil could even increase the therapeutic efficacy of trastuzumab against HER2-overexpressing breast cancer [20] . In spite of being a family of bioactive compounds in flaxseed oil, previous studies on flaxseed LOBs have mainly focused on the immunosuppressive and antimalarial activities of linoorbitide [1-9-N␣C]-linusorb-B3 (LOB3) and its analogues. However, a recent study showed that LOBs increased the oxidative stability of flaxseed oil in their natural matrix and might possess anti-oxidative activity in vivo [21] , implying that LOBs might possess anticancer activities. Furthermore, the calculated log P (logarithm of partition coefficient) values for the LOBs are between 2 and 5 (from ALOGPS, http://www.vcclab.org); making them suitable for both oral and topical administrations according to Lipinski's rule [22] . In the current study, we investigated whether flaxseed LOBs could impose cytotoxic effect towards human breast cancer and melanoma cells.
Materials and methods

Materials
All chemicals used in the current study were purchased from Sigma-Aldrich Canada (Oakville, ON, Canada). The LOBs were a gift from Prairie Tide Chemicals (Saskatoon, SK Canada). Four linoorbitides LOB3, LOB2, [MetO]-LOB2 and [MetO]-LOB1 (Fig. 1) were used in this study. The elution order on a C18 reversed stationary phase liquid chromatograph column is [MetO]-LOB2 < [MetO]-LOB1 < LOB2 < LOB3 (Fig. 2) . Of note is that both [MetO]-LOB2 and [MetO]-LOB1 contain methionine sulfoxide in their ring, which makes them less hydrophobic than their methionine containing counterparts [23] . Stock solutions of the LOBs were prepared in dimethyl sulfoxide (DMSO). Human melanoma cell line A375 and breast cancer cell lines Sk-Br-3 and MCF7 were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). ATCC-formulated cell culture medium for each cell line was purchased from Cedarlane Canada (Burlington, ON, Canada). The CytoTox 96 ® Non-Radioactive Cytotoxicity Assay was purchased from the Promega Corporation (Madison, WI, USA).
Cell culture
Human melanoma cell line A375 and breast cancer cell lines Sk-Br-3 and MCF7 were cultured in T-75 culture flasks under ATCCrecommended cell culture conditions at 5% CO 2 and 37 • C in a Thermo Forma TM Series II Water-Jacketed CO 2 incubator (Thermo Fisher Scientific, Waltham, MA, USA). Cell culture media were changed every 2-3 d for each cell line.
Cytotoxicity assay
The cytotoxicity of LOBs was assayed in three independent experiments with each experiment carried out in triplicate. Briefly, the cultured cells were plated in 96-well plates with 5000 cells/well for cell line A375 and 10,000 cells/well for cell lines Sk-Br-3 and MCF7. The plated cells were allowed to grow to 70-80% confluence before being treated with LOBs for 24 h and 48 h, respectively. The administered concentrations for LOBs were 500 M, 125 M, 31.25 M, 7.85 M and 1.95 M for A375 cells, 400 g/mL, 200 g/mL, 100 g/mL, 50 g/mL and 25 g/mL for Sk-Br-3 cells, and 200 g/mL, 100 g/mL, 50 g/mL, 25 g/mL and 12.5 g/mL for MCF7 cells. As molecular weights for all four LOBs are approximately 1000 daltons, their concentrations were approximately at 1 M ≈ 1 g/mL. Cells treated with DMSO (final concentration at 2%) were used as negative control. Cytotoxicity of the LOBs was measured using the CytoTox96 ® Non-Radioactive Cytotoxicity Assay.
Interaction between LOBs and phospholipid bubbles
Micron-sized phospholipid bubbles were generated by adding 0.5 mg of 1,2-distearoyl-sn-glycero-3-phosphocholine into 15 mL of H 2 O and vortexed (∼900 rpm) at room temperature for 30 s using a VWR analogue vortex mixer. LOB solutions were prepared by adding 1 mg of LOBs to 50 L of 80% methanol. The interaction between LOBs and phospholipid bubbles was investigated by adding 10 L of each respective LOB solution into 100 L bubble suspension, vortexed (∼900 rpm) at room temperature for 30 s, and imaged immediately under a microscope at 100× magnification.
Results and discussion
Cytotoxicity of LOB3, LOB2, [MetO]-LOB2 and [MetO]-LOB1 against melanoma A375 cells were measured at 24 h and 48 h of exposure time, respectively. At 24 h, no cytotoxicity was observed for any of the four LOBs. As the exposure was increased to 48 h, LOB3, [MetO]-LOB2 and [MetO]-LOB1 exhibited increased toxicity of 56%, 32% and 26%, respectively, compared to the control at concentration of 500 M (Fig. 3) . As LOB concentration decreased to 125 M, only LOB3 showed a marginal cytotoxicity of 10%. However, no cytotoxicity was observed for LOB2 at any concentration (Fig. 3) . Subsequently, the cytotoxicity of the four LOBs was measured against breast cancer Sk-Br-3 and MCF7 cells. As shown in Fig. 4 , the respective cytotoxicity of LOB3, LOB2, [MetO]-LOB2 and [MetO]-LOB1 was at 75%, 41%, 36% and 28% towards the SkBr-3 cells after 24 h of exposure at 400 g/mL.
[MetO]-LOB2 and [MetO]-LOB1 only showed cytotoxicity at 400 g/mL; however, both LOB3 and LOB2 exhibited a concentration-dependent cytotoxic response. As the concentration was reduced to 25 g/mL, only 9% and 6% of cytotoxicity were remained for LOB3 and LOB2, respectively. When the exposure time was increased to 48 h, the cytotoxicity of LOB3 was significantly reduced to 45%, whereas LOB2, [MetO]-LOB2 and [MetO]-LOB1 maintained their respective cytotoxicity, at 400 g/mL. For MCF7 cells, the maximum concentration of LOBs used for treatment was 200 g/mL. As illustrated in Fig. 5 , only LOB3 and LOB2 exhibited cytotoxicity at 18% and 19%, respectively, after 24 h of exposure and 7% and 8%, respectively, after 48 h of exposure. This observation was consistent with the experiment on breast cancer Sk-Br-3 cells where it was seen that cytotoxicity of both LOB3 and LOB2 was reduced due to prolonged treatment. We speculated that the cytotoxicity of LOB3 and LOB2 would be much higher at concentration of 400 g/mL based on the experimental results on A375 and Sk-Br-3 cells. Interestingly, [MetO]-LOB2 and [MetO]-LOB1 showed small cytoprotective effects for the MCF7 cells instead of being cytotoxic. In the current study, we showed that the cytotoxicity of LOBs was highly cell-type specific and concentration dependent. Since cancer cells normally retain high levels of reactive oxygen species (ROS), the anti-oxidative activity of LOBs might be important in eliciting their cytotoxic effects against cancer cells. Furthermore, we hypothesized that the hydrophobicity of LOBs might play an essential role in their interaction with cell membranes and this interaction would be the first step towards cytotoxicity. To test our hypothesis, micron-sized phospholipid bubbles were generated to mimic cell membranes for the study of their interaction with LOBs. As shown in Fig. 6 , the order of interacting activity for this model system was [MetO]-LOB2 < [MetO]-LOB1 < LOB2 < LOB3, which was the same as the hydrophobicity order of the LOBs determined by HPLC (Fig. 2) . Continuous observation under a microscope at 100× magnification showed that LOB3 attached to the phospholipid bubbles, which in turn caused rapid aggregation and breakage of the bubbles. LOB2 also caused quick phospholipid bubbles aggregation but broke them at a much slower rate. However, [MetO]-LOB2 exhibited only marginal activity in aggregating phospholipid bubbles. Thus, hydrophobic interaction with cell membrane might be another contributing factor, other than the anti-oxidative function, to the cytotoxic effects of LOBs against human cancer cells.
LOB3 possessed the highest in vitro antitumor activities against all three cancer cell lines at higher concentrations, which is consistent with the observation that LOB3 had higher immunosuppressive function than LOB2 [24] . Taking into consideration of the bioavailability and pharmacokinetic factors, high and/or frequent doses might be needed for oral administered LOB3 to reach a serum concentration of 400-500 g/mL, which is high and uncommon for therapeutic drugs. Although it is impossible to predict how high the oral dose of LOB3 should be without any pharmacokinetic studies, much too high dose requirement would definitely eliminate further exploration on oral administration of LOB3. Intravenous infusion of LOB3 at 400-500 g/mL is likely to be toxic to human and might not be suitable for the treatment of human breast cancer and melanoma. However, cream formulation of LOB3 might be applicable for topical usage against melanoma and perhaps other types of skin cancer. In addition, we observed the cytotoxicity of [MetO]-LOB2 and [MetO]-LOB1 against melanoma A375 and breast cancer Sk-Br-3 cells and LOB2 against breast cancer Sk-Br-3 and MCF7 cells at high concentrations. They experience the same formulation concern. In summary, pure LOBs, which are extracted from flaxseed oil, are unlikely to have any potential as anticancer agents due to the high concentration required for cytotoxicity. Synthetic derivatives of LOBs with better pharmacological activity, bioavailability and pharmacokinetic profile would likely be more applicable in developing LOB-based cancer therapy regimens. Further studies including human breast cancer and melanoma xenograft models are warranted in elucidating the anticancer function of flaxseed LOBs and their derivatives.
